Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone

NCT05680155 is registered in ClinicalTrials.gov with Hangzhou Sciwind Biosciences Co., Ltd. as lead sponsor.

NCT NCT05680155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05680155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone
Lead sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 29, 2022
Completion date
October 12, 2024
Enrollment
211 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

t2dm, type 2 diabetes mellitus